Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesAmortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in IntangiblesChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)DivestmentsFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresLong-Term Debt RepaymentsNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesOther financing activitiesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

BridgeBio Pharma (BBIO) Other Working Capital Changes (2019 - 2025)

BridgeBio Pharma's Other Working Capital Changes history spans 7 years, with the latest figure at -$10.9 million for Q4 2025.

  • For Q4 2025, Other Working Capital Changes fell 141.24% year-over-year to -$10.9 million; the TTM value through Dec 2025 reached -$11.4 million, down 152.24%, while the annual FY2025 figure was -$11.4 million, 152.24% down from the prior year.
  • Other Working Capital Changes for Q4 2025 was -$10.9 million at BridgeBio Pharma, down from -$742000.0 in the prior quarter.
  • Across five years, Other Working Capital Changes topped out at $26.3 million in Q4 2024 and bottomed at -$17.5 million in Q2 2024.
  • The 5-year median for Other Working Capital Changes is -$132500.0 (2021), against an average of $599700.0.
  • The largest YoY upside for Other Working Capital Changes was 9385.42% in 2022 against a maximum downside of 445.65% in 2022.
  • A 5-year view of Other Working Capital Changes shows it stood at $6.1 million in 2021, then plummeted by 114.42% to -$876000.0 in 2022, then skyrocketed by 296.58% to $1.7 million in 2023, then surged by 1429.27% to $26.3 million in 2024, then crashed by 141.24% to -$10.9 million in 2025.
  • Per Business Quant, the three most recent readings for BBIO's Other Working Capital Changes are -$10.9 million (Q4 2025), -$742000.0 (Q3 2025), and -$313000.0 (Q2 2025).